Skip to main content
MedPathMedPath Home
Clinical Trials/NL-OMON22654
NL-OMON22654
Completed
Not Applicable

Bone Marrow Derived Mesenchymal Stem Cells for the Treatment of Refractory Crohn's Disease

eids Universitair Medisch Centrum0 sites10 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsCrohn's Diseasede ziekte van Crohn

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Crohn's Diseasede ziekte van Crohn
Sponsor
eids Universitair Medisch Centrum
Enrollment
10
Status
Completed
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

Duijvestein M, van den Brink GR, Hommes DW. Stem cells as potential novel therapeutic strategy for inflammatory bowel disease. Journal of Crohn's and Colitis (2008) 2, 99¡V106

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional

Investigators

Eligibility Criteria

Inclusion Criteria

  • •1\. Men and women \> 18 years of age.
  • •2\. Subject is willing to participate in the study and has signed the informed consent.

Exclusion Criteria

  • •1\. Patients with evidence of infection or abscesses.
  • •2\. Patients suffering from renal\- or hepatic failure.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Not Applicable
Bone Marrow Derived Mesenchymal Stem Cells for the Treatment of Refractory Crohn*s DiseaseCrohn's Diseasemorbus Crohn10017969
NL-OMON31150eids Universitair Medisch Centrum10
Completed
Not Applicable
Bone marrow derived mesenchymal stem cells for the treatment of allograft rejection after renal transplantatioaandoeningen na niertransplantatieallograft rejectionrejection after (renal) transplantation10038430
NL-OMON31649eids Universitair Medisch Centrum15
Completed
Phase 1
Mesenchymal Stem Cells and Subclinical RejectionOrgan Transplantation
NCT00734396Leiden University Medical Center15
Active, not recruiting
Not Applicable
Mesenchymal stem cell based therapy for the treatment of osteogenesis imperfectaOsteogenesis imperfecta (OI) is a rare genetic disorder with increased bone fragility of varying severity. In the majority of patients the disease is caused by mutations in collagen type I. Severe OI is characterized by osteopenia, frequent fractures, progressive deformity, short stature, loss of mobility, chronic pain and can lead to premature death. At present a cure does not exist.Therapeutic area: Body processes [G] - Cell Physiological Phenomena [G04]
EUCTR2012-002553-38-ESItziar Astigarraga Aguirre
Completed
Phase 1
Perinatal Arterial Stroke Treated With Stromal Cells IntranasallyPerinatal Arterial Ischemic StrokeNeonatal Stroke
NCT03356821UMC Utrecht10